Table 3:
Particle | Amount of enzyme | Duration of treatment | Route of Injection | Source | Tumor Type | Effect | Change in ECM | Ref |
---|---|---|---|---|---|---|---|---|
Caelyx® | 100 µg | 24 hour | Tail vein | Clostridiopeptidase A (Sigma) | OHS osteosarcoma | No change in percent area of imaged tumors exhibiting labeled liposome fluorescence | No detectable change in imaged tumor SHG intensity | 43 |
Doxil | 25 or 125 µg* | 20 hour | Intratumoral + Intravenous | Collagenase 2 (invitrogen) | SCC-4 tongue sarcoma | 2X increase in radiography intensity of labeled liposomes in extracted tumors at.5% dose (IT) | No detectable change in SHG intensity. 35–40% reduction in IFP (under 2 hours IV) (over 2 hours IT) | 60 |
Glycol Chitosan Nanoparticles (300 nm) | 11 or 220 U/mg | 72 hour | Intraturmoral | Collagenase Type 1 (Gibco) | A549 alveolar adenocarcinoma | 1.8X increase in fluorescence intensity of labeled nanoparticles in extracted tumors | Visual reduction in tumor collagen by histology (not quantified) | 62 |
Lipoplexes with CpG plasmid (150 nm) | 300 µg | 4 hour | Intravenous | Clostridium type 1 (Wako Pure Chemical) | LLC lung carcinoma | 1.5X increase in fluorescence intensity of labeled lipoplexes in extracted tumors | 65% reduction in IFP (1 hr after collagenase injection) | 63 |
Collagenase coated Gold nanoparticles (30 nm) | <300 µg* | 24 hour | Intravenous | Clostridium collagenase (Sigma) | A549 alveolar adenocarcinoma | 1.4X increase in percent injected dose of collagenase labeled gold nanoparticles by ICP-OES quantification | N/A | 66 |
Total dose determined assuming a 25g mouse